High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery
- PMID: 39773827
- PMCID: PMC11687390
- DOI: 10.4244/EIJ-D-23-01100
High-risk percutaneous coronary intervention in patients with reduced left ventricular ejection fraction deemed not suitable for surgical revascularisation. A clinical consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) in collaboration with the ESC Working Group on Cardiovascular Surgery
Abstract
This clinical consensus statement of the European Association of Percutaneous Cardiovascular Interventions was developed in association with the European Society of Cardiology Working Group on Cardiovascular Surgery. It aims to define procedural and contemporary technical requirements that may improve the efficacy and safety of percutaneous coronary intervention (PCI), both in the acute phase and at long-term follow-up, in a high-risk cohort of patients on optimal medical therapy when clinical and anatomical high-risk criteria are present that entail unacceptable surgical risks, precluding the feasibility of coronary artery bypass grafting (CABG). This document pertains to patients with surgical contraindication according to the Heart Team, in whom medical therapy has failed (e.g., residual symptoms), and for whom the Heart Team estimates that revascularisation may have a prognostic benefit (e.g., left main, last remaining vessel, multivessel disease with large areas of ischaemia); however, there is a lack of data regarding the size of this patient population. This document aims to guide interventional cardiologists on how to proceed with PCI in such high-risk patients with reduced left ventricular ejection fraction after the decision of the Heart Team is made that CABG - which overall is the guideline-recommended option for revascularisation in these patients - is not an option and that PCI may be beneficial for the patient. Importantly, when a high-risk PCI is planned, a multidisciplinary decision by interventional cardiologists, cardiac surgeons, anaesthetists and non-invasive physicians with expertise in heart failure management and intensive care should be agreed upon after careful consideration of the possible undesirable consequences of PCI, including futility, similar to the approach for structural interventions.
Conflict of interest statement
A. Schäfer received honoraria from Zoll Circulation, AstraZeneca, Amgen, BMS, Pfizer, Daiichi Sankyo, and Boehringer Ingelheim; as well as an institutional grant from Abiomed. C. Collet received honoraria from HeartFlow, Pie Medical Imaging, Boston Scientific, Siemens Healthineers, CathWorks, and Abbott; as well as clinical research grants from HeartFlow and Abbott. T.K. Rudolph received honoraria from Abbott and Philips. A. Roguin received honoraria from Sanofi-Aventis, Novo Nordisk, Novartis, Biotronik, Amgen, and Boehringer Ingelheim. R. Colleran received honoraria from Medtronic; educational grants from Boston Scientific and Abbott; as well as research grants from Biosensors. G. Stefanini received honoraria from Abbott, Boston Scientific, and Pfizer/Bristol-Myers Squibb. T. Lefèvre received honoraria from Edwards Lifesciences, Abbott, Boston Scientific, Terumo, and Medtronic. N. Van Mieghem received honoraria from Abbott, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, Abiomed, PulseCath BV, Amgen, Daiichi Sankyo, and JenaValve; as well as research grants from Abbott, Boston Scientific, Edwards Lifesciences, Medtronic, PulseCath BV, and Daiichi Sankyo. G. Cayla received honoraria from Medtronic, Edwards Lifesciences, MicroPort, Amgen, AstraZeneca, Abbott, Biotronik, Bristol-Myers Squibb, Sanofi-Aventis, and Pfizer. A. Baumbach received honoraria from Faraday, JenaValve, MicroPort, Pi-Cardia, and AstraZeneca. A. Witkowski received honoraria from Boston Scientific and Abbott. F. Burzotta received honoraria from Abiomed, Abbott, Medtronic, and Terumo. D. Capodanno received honoraria from Bayer, AstraZeneca, Amgen, Daiichi Sankyo, Boehringer Ingelheim, Biotronik, Medtronic, and Menarini; he is a minor shareholder with CERC. R. Al-Lamee received honoraria from Abbott, Menarini, and Philips. A. Banning received honoraria from Miracor, Boston Scientific, Shockwave Medical, and Abbott. P. MacCarthy received research grants from Boston Scientific; and honoraria from Edwards Lifesciences. R. Gottardi is a minor shareholder with Tevar Ltd. F.S. Schoenhoff received a research grant from Three Hearts Foundation; and honoraria from Vascular International. M. Czerny received honoraria from Terumo Aortic, Medtronic, and Endospan; and is a shareholder with TEVAR Ltd and Ascense Medical. M. Thielmann received honoraria from Cytosorbents. N. Werner received honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Boston Scientific, Abiomed, Daiichi Sankyo, and Shockwave Medical; as well as research grants from Shockwave Medical and Abiomed. G. Tarantini received honoraria from Abbott, Abiomed, Medtronic, Boston Scientific, Edwards Lifesciences, MicroPort, and GADA. The other authors have no conflicts of interest to declare. The Guest Editor reports consultancy fees from Novartis and Meril Life Sciences; speaker honoraria from Boston Scientific, Amgen, Daiichi Sankyo, and Meril Life Sciences; speaker honoraria paid to his institution from BMS/Pfizer, Daiichi Sankyo, Boston Scientific, Siemens, and Amgen; and research grants paid to his institution from Boston Scientific and Abbott.
References
-
- Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, de Ferranti, Després JP, Fullerton HJ, Howard VJ, Huffman MD, Judd SE, Kissela BM, Lackland DT, Lichtman JH, Lisabeth LD, Liu S, Mackey RH, Matchar DB, McGuire DK, Mohler ER, Moy CS, Muntner P, Mussolino ME, Nasir K, Neumar RW, Nichol G, Palaniappan L, Pandey DK, Reeves MJ, Rodriguez CJ, Sorlie PD, Stein J, Towfighi A, Turan TN, Virani SS, Willey JZ, Woo D, Yeh RW, Turner MB American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–322. - PubMed
-
- Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CSP, Sato N, Shah AN, Gheorghiade M. The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol. 2014;63:1123–33. - PubMed
-
- Neumann FJ, Sousa-Uva M, Ahlsson A, Alfonso F, Banning AP, Benedetto U, Byrne RA, Collet JP, Falk V, Head SJ, Jüni P, Kastrati A, Koller A, Kristensen SD, Niebauer J, Richter DJ, Seferović PM, Sibbing D, Stefanini GG, Windecker S, Yadav R, Zembala MO. 2018 ESC/EACTS Guidelines on myocardial revascularization. EuroIntervention. 2019;14:1435–534. - PubMed
-
- Shields MC, Ouellette M, Kiefer N, Kohan L, Taylor AM, Ailawadi G, Ragosta M. Characteristics and outcomes of surgically ineligible patients with multivessel disease treated with percutaneous coronary intervention. Catheter Cardiovasc Interv. 2021;98:1223–9. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Miscellaneous
